文献速递其他结缔组织病

血小板与C反应蛋白升高与系统性硬化症严重疾病及不良生存相关

Association of Elevated Platelets and C-Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2026-07-22

双升高组(EP/EC)疾病表现最重、改良Rodnan皮肤评分最高、中位生存期最短(9.6年 vs 21.3年),调整风险比7.34。结论提示血小板联合CRP升高可识别重症及生存差的患者。

要点

  • 血小板≥330,000/μL且CRP≥6.0 mg/L的SSc患者疾病表现最重、生存最差。
  • 双升高组中位生存9.6年,调整风险比7.34(95%CI 2.40-22.41)。
  • 孤立CRP或血小板升高者疾病严重程度介于双升高与正常组之间。

核心结论

  • 血小板升高联合CRP升高可识别系统性硬化症中疾病严重且生存差的患者。

研究设计与样本

  • 采用症状出现后首次抽血结果,以血小板≥330,000/μL和CRP≥6.0 mg/L为切点分为四组。

主要发现

  • EP/EC组Scl-70抗体阳性、弥漫性皮肤受累、心肌炎/心肌病、吞咽困难、胃窦血管扩张、关节挛缩和指端溃疡的发生率最高(P < 0.05)。
  • EP/EC组在整个两年期间改良Rodnan皮肤评分最高(P < 0.05)。
  • EP/EC组中位生存期最低(9.6年 vs NP/NC组21.3年,P < 0.0001),调整风险比7.34(95% CI 2.40-22.41,Bonferroni校正P = 0.0025)。
  • NP/NC组基线用力肺活量最佳且两年内保持稳定,但组间随时间差异无统计学意义。
  • 孤立CRP或血小板升高组疾病严重程度介于双升高组与正常组之间。

关键数值与推荐

  • 血小板升高切点为≥330,000/μL,CRP升高切点为≥6.0 mg/L。
  • 分组:NP/NC 84例(60%),NP/EC 33例(24%),EP/NC 10例(7%),EP/EC 12例(9%)。

临床怎么用

  • 对系统性硬化症患者可联合评估血小板和CRP水平,双升高者提示需积极筛查和治疗并发症。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Elevated C-reactive protein (CRP) levels in systemic sclerosis (SSc) have been linked with severe disease and worse survival, but the role of platelet levels remains unclear. This study examined whether elevated platelet levels, CRP levels, or both are associated with disease severity, progression, and survival in SSc. METHODS: We performed a retrospective study of adult patients with SSc seen from 1996 to 2022. Using the first blood draw after symptom onset, patients were categorized into four groups using cutoffs of ≥330,000/μL for platelets and ≥6.0 mg/L for CRP: (1) normal platelet/normal CRP (NP/NC), (2) normal platelet/elevated CRP (NP/EC), (3) elevated platelet/normal CRP (EP/NC), (4) elevated platelet/elevated CRP (EP/EC). RESULTS: One hundred and thirty-nine patients were included (84 NP/NC [60%], 33 NP/EC [24%], 10 EP/NC [7%], and 12 EP/EC [9%]). The EP/EC had the highest rates of Scl-70 antibody positivity, diffuse skin involvement, myocarditis/cardiomyopathy, dysphagia, gastric antral vascular ectasia, joint contractures, and digital ulcers (P < 0.05). NP/NC had the best baseline forced vital capacity, which remained stable over two years, though differences among groups over time were not significant. EP/EC had the highest modified Rodnan skin scores throughout the two-year period (P < 0.05). Median survival was lowest in the EP/EC group (9.6 years vs 21.3 years in NP/NC, P < 0.0001), with an adjusted hazard ratio of 7.34 (95% CI 2.40-22.41, Bonferroni-adjusted P = 0.0025). Patients with isolated CRP or platelet elevation demonstrated intermediate disease severity compared with the dual-elevation group. CONCLUSION: Elevated platelet levels in combination with elevated CRP levels identifies patients with SSc with severe disease and poor survival, who may warrant aggressive screening and treatment of complications.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Lee BS, Li S, Davuluri S, et al. Association of Elevated Platelets and C-Reactive Protein With Severe Disease and Poor Survival in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2026. PMID: 42485654. doi:10.1002/acr.80116

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。